Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Haematologica|February 11, 2010
The Southern French registry of genetic hemochromatosis: a tool for determining clinical prevalence of the disorder and genotype penetrancePatricia Aguilar-Martinez, Michael Bismuth, François Blanc, et al.
Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.
Plos One|March 17, 2016
A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver DiseasesBertrand Nalpas, Philippe Ichaï, Laure Jamot, et al.
Digestive Diseases and Sciences|January 29, 2016
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in FrancePatrick Marcellin, Fabien Zoulim, Christophe Hézode, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosisArmand Abergel, Tarik Asselah, Arianne Mallat, et al.
Digestive Diseases and Sciences|April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in FranceDenis Ouzan, Dominique Larrey, Dominique Guyader, et al.
JHEP Reports : Innovation in Hepatology|May 4, 2023
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohortLina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, et al.
Clinical Pharmacology and Therapeutics|November 2, 2020
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug RegimensPaola Nicoletti, Harshad Devarbhavi, Ashish Goel, et al.
Pageof 14